Abraxis BioScience Receives FDA Approval for Oxytocin Injection 10 USP Units/mL in a 30 mL Vial

  
    
  
  
    
      Abraxis BioScience, Inc. (NASDAQ: ABBI), an integrated, global 
      biopharmaceutical company, today announced that its hospital-based 
      products business, Abraxis Pharmaceutical Products (APP), has received 
      approval from the U.S. Food and Drug Administration (FDA) for its 
      Supplemental New Drug Application (sNDA) for Oxytocin Injection, USP, 30 
      mL.
    
    
      As the market leader, APP currently manufactures and distributes 
      Oxytocin in 1mL and 10 mL vials, and this unique 30mL code is expected 
      to further secure APP�s position. The company 
      will distribute this larger, more convenient size in multi-dose vials 
      with latex-free stoppers and expects to commence marketing of this 
      product in the third quarter of 2007. According to IMS data, annual 
      sales in 2006 of this product across all distributors and dosage forms 
      were approximately $33 million.
    
    
      Oxytocin Injection is indicated for the initiation or improvement of 
      uterine contractions, where this is desirable and considered suitable 
      for reasons of fetal or maternal concern, in order to achieve vaginal 
      delivery. It is also indicated to produce uterine contractions during 
      the third stage of labor and to control postpartum bleeding or 
      hemorrhage.
    
    
      APP manufactures and markets one of the most comprehensive injectable 
      portfolios of products to the U.S. hospital-based market. The current 
      injectable portfolio is comprised of anti-infectives, critical care, 
      oncology and anesthetic/analgesic products totaling over 400 dosage 
      forms. Including those ANDAs pending with the FDA, APP currently has 
      over 60 product candidates in various stages of development.
    
    
      About Abraxis BioScience, Inc.
    
    
      Abraxis BioScience, Inc. is an integrated global biopharmaceutical 
      company dedicated to meeting the needs of critically ill patients. The 
      company develops, manufactures and markets one of the broadest 
      portfolios of injectable products and leverages revolutionary technology 
      such as its nab� platform to discover 
      and deliver breakthrough therapeutics that transform the treatment of 
      cancer and other life-threatening diseases. The first FDA approved 
      product to use this nab platform, ABRAXANE�, 
      was launched in 2005 for the treatment of metastatic breast cancer. 
      Abraxis trades on the Nasdaq Global Market under the symbol ABBI. For 
      more information about the company and its products, please visit www.abraxisbio.com.